Verapamil and beta cell function in adults with recent-onset type 1 diabetes
Fernando Ovalle, Tiffany Grimes, Guanlan Xu, Anish J Patel, Truman B Grayson, Lance A Thielen, Peng Li, Anath Shalev, Fernando Ovalle, Tiffany Grimes, Guanlan Xu, Anish J Patel, Truman B Grayson, Lance A Thielen, Peng Li, Anath Shalev
Abstract
Pancreatic beta cell loss is a key factor in the pathogenesis of type 1 diabetes (T1D), but therapies to halt this process are lacking. We previously reported that the approved antihypertensive calcium-channel blocker verapamil, by decreasing the expression of thioredoxin-interacting protein, promotes the survival of insulin-producing beta cells and reverses diabetes in mouse models1. To translate these findings into humans, we conducted a randomized double-blind placebo-controlled phase 2 clinical trial ( NCT02372253 ) to assess the efficacy and safety of oral verapamil added for 12 months to a standard insulin regimen in adult subjects with recent-onset T1D. Verapamil treatment, compared with placebo was well tolerated and associated with an improved mixed-meal-stimulated C-peptide area under the curve, a measure of endogenous beta cell function, at 3 and 12 months (prespecified primary endpoint), as well as with a lower increase in insulin requirements, fewer hypoglycemic events and on-target glycemic control (secondary endpoints). Thus, addition of once-daily oral verapamil may be a safe and effective novel approach to promote endogenous beta cell function and reduce insulin requirements and hypoglycemic episodes in adult individuals with recent-onset T1D.
Conflict of interest statement
COMPETING FINANCIAL INTERESTS STATEMENT
None of the authors have any interests to declare.
Figures
References
- Xu G, Chen J, Jing G & Shalev A Preventing beta-Cell Loss and Diabetes With Calcium Channel Blockers. Diabetes 61, 848–856 (2012).
- Davis AK, et al. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 38, 476–481 (2015).
- Liu EH, et al. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia 52, 1369–1380 (2009).
- Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 128, 517–523 (1998).
- Shalev A, et al. Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology 143, 3695–3698 (2002).
- Chen J, et al. Thioredoxin-Interacting Protein Deficiency Induces Akt/Bcl-xL Signaling and Pancreatic Beta Cell Mass and Protects Against Diabetes. FASEB J 22, 3581–3594 (2008).
- Chen J, Saxena G, Mungrue IN, Lusis AJ & Shalev A Thioredoxin-Interacting Protein: A Critical Link between Glucose Toxicity and Beta Cell Apoptosis. Diabetes 57, 938–944 (2008).
- Minn AH, Hafele C & Shalev A Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146, 2397–2405 (2005).
- Minn AH, et al. Gene expression profiling in INS-1 cells overexpressing thioredoxin-interacting protein. Biochem Biophys Res Commun 336, 770–778 (2005).
- Chen J, Cha-Molstad H, Szabo A & Shalev A Diabetes Induces and Calcium Channel Blockers Prevent Cardiac Expression of Pro-Apoptotic Thioredoxin-Interacting Protein. Am J Physiol Endocrinol Metab 296, 1133–1139 (2009).
- Afzal N, et al. Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 37, 936–942 (1988).
- Cohn RD, et al. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J Clin Invest 107, R1–7 (2001).
- Xu G, Chen J, Jing G & Shalev A Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nat Med (2013).
- Jo S, et al. miR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function. Diabetes 67, 256–264 (2018).
- Zhou R, Tardivel A, Thorens B, Choi I & Tschopp J Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11, 136–140 (2010).
- Yin T, Kuo SC, Chang YY, Chen YT & Wang KK Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus. J Clin Endocrinol Metab 102, 2604–2610 (2017).
- Cooper-Dehoff R, et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 98, 890–894 (2006).
- Cooper-DeHoff RM, et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J 151, 1072–1079 (2006).
- Busch Sorensen M, et al. Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus. European journal of clinical pharmacology 41, 401–404 (1991).
- Khodneva Y, Shalev A, Frank SJ, Carson AP & Safford MM Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study. Diabetes Res Clin Pract 115, 115–121 (2016).
- Nambam B, Bratina N & Schatz D Immune Interventions for Type 1 Diabetes Mellitus. Diabetes technology & therapeutics 19, S74–S81 (2017).
- Alhadj Ali M, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Science translational medicine 9(2017).
- Herold KC, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. The New England journal of medicine 346, 1692–1698 (2002).
- Aronson R, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 37, 2746–2754 (2014).
- Pescovitz MD, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. The New England journal of medicine 361, 2143–2152 (2009).
- Pozzilli P, Maddaloni E & Buzzetti R Combination immunotherapies for type 1 diabetes mellitus. Nature reviews. Endocrinology 11, 289–297 (2015).
- Greenbaum CJ, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 61, 2066–2073 (2012).
- Hao W, et al. Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care 39, 1664–1670 (2016).
- Greenbaum CJ, et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31, 1966–1971 (2008).
- Palmer JP, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes 53, 250–264 (2004).
- Lachin JM, et al. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. PLoS One 6, e26471 (2011).
- Moore CG, Carter RE, Nietert PJ & Stewart PW Recommendations for planning pilot studies in clinical and translational research. Clinical and translational science 4, 332–337 (2011).
- Li P, Stuart EA & Allison DB Multiple Imputation: A Flexible Tool for Handling Missing Data. JAMA 314, 1966–1967 (2015).
Source: PubMed